कोशिश गोल्ड - मुक्त
Persistent beats demand dip in Q2. Can it hit $2 bn revenue?
Mint Mumbai
|October 17, 2025
Persistent Systems Ltd is handling the muted demand scenario in the IT sector well. In Q2FY26, the tier-II company’s sequential constant currency revenue grew 4.4%, exceeding the consensus estimate of 3.5%.
This pushed the stock up more than 8% in the past two days. Growth was broadbased, led by momentum in the banking, financial services, and insurance (BFSI) vertical, healthcare and the Europe geography.
After a muted first quarter, lender fared better on many paramdeal wins gained traction in Q2FY26, aiding revenue visibility. The trailing 12-month total contract value rose 15% year-on-year (yo-y) to $609 million, implying a 1.5x bookto-bill ratio, while quarterly annual contract value bookings grew 28%.
Given the robust deal pipeline and strong execution seen so far, the management reiterated its $2 billion revenue ambition for FY27. It is banking on strong growth in FY26 led by BFSI and hi-tech, with healthcare gradually recovering.
Earnings before interest and tax (Ebit) margin rose 80 bps q-o-q to 16.3% in Q2FY26, beating the 15.7% estimate. Lower software costs, currency gains, and offshore shift offset higher provisions and softer utilisation.
यह कहानी Mint Mumbai के October 17, 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Mint Mumbai से और कहानियाँ

Mint Mumbai
12 states, UTs support e-bus payment plan
PM E-bus Sewa PSM scheme plans to build confidence in e-bus makers
2 mins
October 18, 2025
Mint Mumbai
Govt plans highway network to expand road grid
The officials did not disclose the planned length of the proposed high-speed expressways or the investment.
1 min
October 18, 2025
Mint Mumbai
SC allows Natco to sell generic of Roche drug until case ends
The Supreme Court on Friday rejected Swiss pharmaceutical giant F. Hoffmann-La Roche AG's (Roche) pleaseeking that Natco Pharma Ltd berestricted from selling the generic version of its lifesaving spinal muscular atrophy (SMA) drug, Risdiplam, in India until the conclusion of the case.
2 mins
October 18, 2025

Mint Mumbai
Dixon meets revenue goal in Q2, bets on components
Topline grows 33% on year to ₹14,855 cr, unsold goods from Q1 drive profits in Sep quarter
3 mins
October 18, 2025

Mint Mumbai
Play it again, Diane Keaton
Who would not fall in love with Diane Keaton?
4 mins
October 18, 2025
Mint Mumbai
India avoids FTAs with rivals, backs own agenda’
The government is steering clear of free trade agreements (FTAs) with countries that directly compete with Indian industry and instead is focusing on countries that complement India’s economic priorities, commerce and industry minister Piyush Goyal said on Friday.
1 min
October 18, 2025

Mint Mumbai
Walmart, once a byword for low pay, becomes a case study in how to treat workers
The largest private employer in the U.S. increased wages to jump-start sales. Investors needed to be convinced.
6 mins
October 18, 2025

Mint Mumbai
Tales of women who write their own rules
Shanta Gokhale's new collection of short stories, 'The Way Home', is informed by humanity, wit, worldly wisdom and lived experiences
3 mins
October 18, 2025
Mint Mumbai
Oracle isn’t answering the hardest questions about its AI plans
I hype has been very lucrative for Oracle .AI fatigue could prove painful.
3 mins
October 18, 2025

Mint Mumbai
Global bank stocks shiver as US credit risks spark checks
Fear over credit quality in US regional banks rippled through markets on Friday, dragging global financial stocks lower and reviving memories of the crisis of confidence that shook sentiment just over two years ago.
1 mins
October 18, 2025
Listen
Translate
Change font size